Why has the United States handled this pandemic so badly? The Editors note that although we came into this crisis with enormous advantages, our current political leaders have demonstrated that they are dangerously incompetent.
Fantastic work by @singh_kavisha which showcased the role of simulation in assessment of cardiology fellow performance in TTE scanning that's especially relevant in the COVID-19 era. @UTSWCardfellow
https://t.co/RwR5syzKAp
The cholesterol story is never simple. Our work on multi ethnic cohorts from the US/Europe to see how HDL particles a/w vascular events and how that compares to HDL-C with @dranandrohatgi@AlvinChandraMD@DrPJoshi@dramitkhera@utswheart & others. https://t.co/5LivUWo8VV
So proud to share this @JAMACardio article written by my friend and colleague Dr. Riccardo Inciardi who's at the front line fighting #COVID19 in Italy. Also featured @nytimes. Thank you for sharing your valuable experience!
https://t.co/brqIdHhD4W
https://t.co/KmEuaNHErw
Striking data in @ESC_Journals#EJHF by @PeterMoliner: How do pts with HFrEF die? The answer appears to be changing if asked in 2001 vs 2018. Reflects treatment successes & new challenges!
Our accompanying editorial @RBPatelMD#AnjuNohria@JavedButler1
https://t.co/DFBGbBNLIE
📍Health-Related Quality of Life in HFpEF: PARAGON-HF Trial (compared with PARADIGM trial)
📌 HRQL was largely worse in women and was similar in HFpEF and HFrEF
@JACCJournals@secardiologia@SACardiologia
https://t.co/ED3HzBrnFf
Long-awaited #PROVEHF did not disappoint 🙌🏻:
-Rapid (<2w) and large reduction in NT-proBNP (at lowest #entresto dose)
-Sign reverse remodelling (LVEF +9% and LVMi -16 g/m2)
-Consistent in RASi-naive; low NP and non-target dose
CONGRATULATIONS @JJheart_doc @scottdsolomon
#PARAGONHF p=0.058 for primary endpoint: HR 0.87 (0.75-1.01)
👁Super interesting sex differences: HR 0.73 (0.59-0.90) in 👩🏻🦳 and 1.03 (0.85-1.25) in👨🏻🦳
👁Signal of better treatment effect with lower EF
Let the debate begin!
https://t.co/quU5zviG0q
@Novartis@scottdsolomon
In this post hoc secondary analysis of the PARADIGM-HF trial, sacubitril/valsartan improved limitations in physical + social activities that are common in patients with heart failure, including sexual activities #Entresto#NeprilysinInhibitor#HeartFailure https://t.co/KJ54IDKJe5
Happy to share our findings published at #JACC from the #DallasHeartStudy regarding the association of temporal changes in body fat distribution and #hypertension
New #JACC paper examines the association of temporal changes in body fat distribution with #hypertension in a multi-ethnic cohort. https://t.co/PbFDAGN6dm